沙美特罗吸入剂治疗小儿支气管哮喘临床分析.docVIP

沙美特罗吸入剂治疗小儿支气管哮喘临床分析 　　【摘要】目的 探讨沙美特罗吸入剂治疗小儿支气管哮喘的临床疗效。方法 选取我院收治的支气管哮喘患儿100例组作为研究对象，随机分为治疗组和对照组，对照组患儿吸入氟替卡松（FP）治疗，治疗组患儿应用沙美特罗/氟替卡松治疗，比较两组患儿的临床疗效及对IP-10水平的影响。结果 治疗组患儿疗效好、IP-10下降明显，与对照组患者比较差异有统计学意义（p＜0.05）。结论 IP-10参与哮喘的发病，哮喘患儿吸入长效β受体激动剂，能明显改善患儿的临床症状，并显著降低血清IP-10水平。 　　【关键词】沙美特罗吸入剂 支气管哮喘 IP-10 临床疗效 　　中图分类号：R725.6文献标识码：A文章编号：1005-0515（2011）12-021-02 　　Clinical analysis of anapnotherapy with Sameterol in pediatric bronchus asthma 　　HU Canhui 1 YANG Zhou2 　　（1.Peoples Hospital in Yiyang City, Yiyang, Hunan 413000；2.Childrens Hospital in Hunan Province,Changsha, Hunan 410007） 　　【Abstract】Objective to study the clinical curative effect of anapnotherapy with Sameterol in pediatric bronchial asthma. Methods 100 patients of bronchus asthma in Department of pediatric were chosen and radomly devided as control and contrast groups .Patients in control group received anapnotherapy with fluticasone (FP), while Sameterol added to those in the contrast group.Comparison of clinical effects and of the influence upon IP-10 level were therefore made within the two groups. Results Significant clinical effect and decrease in IP-10 occurred in patients of control group.Based on the statistic analyse, the result of control group excelled those in contrast group(p0.05). Conclusion IP-10 contributes to the ocurrance of asthma.Long-term anapnotherapy of βreceptor agonists can significantly improve clinical symptoms in pediatric patients and induce a manifest decrease in IP-10 level. 　　【key words】Anapnotherapy with Sameterol Bronchus Asthma IP-10 Clinical Effect 　　支气管哮喘的发病机制复杂，本质是气道慢性炎症，其中Th1/Th2细胞失衡是哮喘发病机制之一，哮喘患者Th1型免疫反应减弱、Th2反应增强[1]，有文献报道重度哮喘患者中干扰素诱导蛋白（IP-10）水平明显升高，IP-10属于Th1细胞趋化因子，在小鼠哮喘模型及急性发作期哮喘患儿中有类似发现，临床上可将IP-10作为评价哮喘治疗效果的指标。皮质激素和长效β2受体激动剂是目前治疗支气管的常用药物，两类药物均能有效控制哮喘患儿急性发作，本文介绍两类药物联合应用治疗支气管哮喘患儿的临床疗效及对IP-10的影响，现报告如下： 　　1 资料和方法 　　1.1 一般资料 　　选取我院2009年5月~2011年5月收治的100例急性支气管哮喘患儿的临床资料，随机分为治疗组（50例）和对照组（50例），治疗组男性27例，女性23例，年龄在3~14岁之间，平均（7.2±2.1）岁，中度哮喘31例，重度哮喘19例；对照组男性28例，女性22例，年龄在3~13岁之间，